Response of 33 UK patients with infantileâ€•onset Pomp therapy

Journal of Inherited Metabolic Disease

39, 261-271

DOI: 10.1007/s10545-015-9898-5

Citation Report

#	Article	IF	Citations
1	From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2016, 5, e361.	2.3	29
2	High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Molecular Genetics and Metabolism, 2017, 122, 76-79.	0.5	7
3	Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease. Acta Neurologica Scandinavica, 2017, 136, 558-569.	1.0	10
4	Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?. JIMD Reports, 2017, 39, 55-62.	0.7	19
5	High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy. Journal of Pediatrics, 2018, 195, 236-243.e3.	0.9	27
6	Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Developmental Medicine and Child Neurology, 2018, 60, 579-586.	1.1	77
7	The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients. Molecular Genetics and Metabolism Reports, 2018, 15, 50-54.	0.4	9
8	Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet Journal of Rare Diseases, 2018, 13, 32.	1.2	65
9	Pompe disease in Austria: clinical, genetic and epidemiological aspects. Journal of Neurology, 2018, 265, 159-164.	1.8	29
10	Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543.	1.5	9
11	Cardiac outcome in classic infantile Pompe disease after 13â€¯years of treatment with recombinant human acid alpha-glucosidase. International Journal of Cardiology, 2018, 269, 104-110.	0.8	32
12	Biochemical and clinical aspects of glycogen storage diseases. Journal of Endocrinology, 2018, 238, R131-R141.	1.2	67
13	Extension of the Pompe mutation database by linking diseaseâ€associated variants to clinical severity. Human Mutation, 2019, 40, 1954-1967.	1.1	47
14	Comprehensive approach to weaning in difficult-to-wean infantile and juvenile-onset glycogen-storage disease type II patients: a case series. Italian Journal of Pediatrics, 2019, 45, 106.	1.0	1
15	New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges. Expert Review of Clinical Pharmacology, 2019, 12, 757-770.	1.3	12
16	Effects of immunomodulation in classic infantile Pompe patients with high antibody titers. Orphanet Journal of Rare Diseases, 2019, 14, 71.	1.2	21
17	Respiratory complications of metabolic disease in the paediatric population: A review of presentation, diagnosis and therapeutic options. Paediatric Respiratory Reviews, 2019, 32, 55-65.	1.2	5
18	Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I. Molecular Therapy - Methods and Clinical Development, 2019, 13, 321-333.	1.8	9

#	Article	IF	Citations
19	Treating lysosomal storage disorders: What have we learnt?. Journal of Inherited Metabolic Disease, 2020, 43, 125-132.	1.7	20
20	Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Molecular Genetics and Metabolism Reports, 2020, 23, 100591.	0.4	23
21	Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on longâ€term clinical outcome of classic infantile Pompe patients. Journal of Inherited Metabolic Disease, 2020, 43, 1243-1253.	1.7	22
22	Diagnosis and Care of Infants and Children with Pompe Disease. Klinische Padiatrie, 2020, 232, 55-61.	0.2	3
23	Skeletal muscle magnetic resonance imaging in <scp>Pompe</scp> disease. Muscle and Nerve, 2021, 63, 640-650.	1.0	18
24	Pulmonary Manifestations of Endocrine and Metabolic Diseases in Children. Pediatric Clinics of North America, 2021, 68, 81-102.	0.9	0
25	Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genetics in Medicine, 2021, 23, 845-855.	1.1	26
26	Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease. Orphanet Journal of Rare Diseases, 2021, 16, 235.	1.2	18
27	The Glycogen Storage Diseases and Related Disorders. , 2016, , 121-137.		9
28	Sustained immune tolerance induction in enzyme replacement therapyâ€“treated CRIM-negative patients with infantile Pompe disease. JCI Insight, 2017, 2, .	2.3	47
29	Long-term outcome and unmet needs in infantile-onset Pompe disease. Annals of Translational Medicine, 2019, 7, 283-283.	0.7	40
30	Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Annals of Translational Medicine, 2019, 7, 285-285.	0.7	38
32	Improvement in Cardiac Function With Enzyme Replacement Therapy in a Patient With Infantile-Onset Pompe Disease. Ochsner Journal, 2018, 18, 413-416.	0.5	3
33	Inherited Cardiovascular Metabolic Disorders. , 2018, , 189-237.		0
34	Glycogen Storage Diseases. , 2018, , 20-21.		0
35	Clinical and Technological Dependence Characteristics on a Series of Brazilian Cases with Infantile Onset Pompe Disease in Enzyme Replacement Therapy. Open Journal of Clinical Diagnostics, 2019, 09, 16-32.	0.3	0
36	Glykogenspeicherkrankheiten. Basiswissen Psychologie, 2019, , 1-14.	0.0	0
37	Infantile Pompe disease treatment with Myozyme in Chaharmahal and Bakhtiari: A case report. Journal of Shahrekord University of Medical Sciences, 2019, 21, 149-152.	0.2	0

#	Article	IF	Citations
38	Glykogenspeicherkrankheiten. Springer Reference Medizin, 2020, , 769-782.	0.0	0
39	Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement. Frontiers in Neurology, 2020, 11, 569153.	1.1	6
41	Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. The Lancet Child and Adolescent Health, 2022, 6, 28-37.	2.7	27
42	Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel. Italian Journal of Pediatrics, 2022, 48, 41.	1.0	6
43	Advances in diagnosis and management of Pompe disease. Medycyna Wieku Rozwojowego, 2020, 24, 3-8.	0.2	6
44	Lentiviral gene therapy prevents anti-human acid Î±-glucosidase antibody formation in murine Pompe disease. Molecular Therapy - Methods and Clinical Development, 2022, 25, 520-532.	1.8	9
45	The earliest enzyme replacement for infantileâ€onset Pompe disease in Japan. Pediatrics International, 2022, 64, .	0.2	0
46	Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Molecular Genetics and Metabolism Reports, 2022, 33, 100929.	0.4	8
47	Pompe disease, a rare condition in two patients, case reports. , 2023, 1, .		0